Craniosynostosis, a condition where skull sutures fuse prematurely in children, can raise concerns about intracranial hypertension (ICH) – increased pressure within the skull. Traditionally, diagnosing ICH relies on invasive procedures. This review examines a promising new approach: handheld optical coherence tomography (OCT). Analyzing studies on handheld OCT use in children with craniosynostosis, we explore its feasibility, advantages, and potential role in improving diagnosis and patient care.
Craniosynostosis affects 1 in 2,000 newborns, often requiring surgery to correct skull shape and prevent complications. A significant concern is intracranial hypertension (ICH), which can damage the brain and vision if left untreated. Traditionally, diagnosing ICH involves invasive procedures like lumbar punctures or intracranial pressure monitoring. These methods are not ideal for young children, prompting the search for non-invasive alternatives.
Optical coherence tomography (OCT) is a revolutionary imaging technique that uses light to create detailed cross-sectional images of tissues. Recent advancements have led to the development of handheld OCT devices, making them more portable and user-friendly for pediatric applications. This review focuses on the feasibility of handheld OCT in diagnosing ICH in children with craniosynostosis.
Several studies have explored the use of handheld OCT in this context. These studies demonstrate promising results:
High Success Rates: Studies report successful image acquisition in a high percentage of children, exceeding 80% in some cases.
Feasibility for Young Children: Handheld OCT appears well-suited for young children, with good compliance and minimal discomfort.
Repeatability: Studies suggest good repeatability of OCT measurements, allowing for monitoring of pressure changes over time.
Handheld OCT offers several advantages over traditional methods for diagnosing ICH in children with craniosynostosis:
Non-invasive: Eliminates the need for needles or sedation, reducing risks and discomfort for children.
Quick and painless: OCT scans are completed in seconds, minimizing stress for patients.
Portable: Handheld devices allow for examinations at the bedside, improving accessibility.
Objective data: OCT provides quantitative measurements, aiding in diagnosis and monitoring.
While these initial studies are encouraging, further research is needed to fully establish handheld OCT as a standard diagnostic tool for ICH in children with craniosynostosis. Larger, multicenter trials are crucial to confirm its effectiveness and identify potential limitations. Additionally, exploring the correlation between OCT findings and other measures of ICH is important.
Handheld OCT holds immense potential for revolutionizing the diagnosis of ICH in children with craniosynostosis. This review highlights the feasibility, advantages, and future directions for this promising non-invasive technology. As research progresses, handheld OCT may become a valuable tool in improving early detection and management of ICH, leading to better outcomes for young patients.
1.
Study finds 81% of cancer cures touted by TikTok videos are fake
2.
Telemedicine Not Reaching Rural Psychiatric Patients
3.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
4.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
5.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
1.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
2.
Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Updates on Standard V/S High Risk Myeloma Treatment
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation